WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401903
CAS#: 280744-09-4
Description: SB-216763 is a glycogen synthase kinase-3 (GSK3) inhibitor, which can maintain mouse embryonic stem cells (mESCs) in a pluripotent state in the absence of exogenous leukemia inhibitory factor (LIF) when cultured on mouse embryonic fibroblasts (MEFs). SB-216763 is the first GSK3 inhibitor that can promote self-renewal of mESC co-cultured with MEFs for more than two months.
MedKoo Cat#: 401903
Name: SB-216763
CAS#: 280744-09-4
Chemical Formula: C19H12Cl2N2O2
Exact Mass: 370.02758
Molecular Weight: 371.22
Elemental Analysis: C, 61.47; H, 3.26; Cl, 19.10; N, 7.55; O, 8.62
SB-216763, purity > 98%, is in stock. The same day shipping after order is received.
Synonym: SB216763; SB 216763; SB-216763
IUPAC/Chemical Name: 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
InChi Key: JCSGFHVFHSKIJH-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)
SMILES Code: O=C(C(C1=CC=C(Cl)C=C1Cl)=C2C3=CN(C)C4=C3C=CC=C4)NC2=O
The following data is based on the product molecular weight 371.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zhong JQ, Xie YK, Ji XK, Fu JH, Wang Y, Zhang QY, Shi HQ, Shan YF. [Effects of glycogen synthase kinase 3β overexpression in rat and glycogen synthase kinase 3β inhibitor SB-216763 on proliferation of hepatic oval cells]. Zhonghua Wai Ke Za Zhi. 2012 Nov;50(11):1003-6. Chinese. PubMed PMID: 23302485.
2: Kirby LA, Schott JT, Noble BL, Mendez DC, Caseley PS, Peterson SC, Routledge TJ, Patel NV. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells. PLoS One. 2012;7(6):e39329. doi: 10.1371/journal.pone.0039329. Epub 2012 Jun 26. PubMed PMID: 22745733; PubMed Central PMCID: PMC3383737.
3: Wang M, Gao M, Miller KD, Sledge GW, Hutchins GD, Zheng QH. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2011 Jan 1;21(1):245-9. doi: 10.1016/j.bmcl.2010.11.026. Epub 2010 Nov 11. PubMed PMID: 21115250.
4: Couvreur N, Tissier R, Pons S, Chenoune M, Waintraub X, Berdeaux A, Ghaleh B. The ceiling effect of pharmacological postconditioning with the phytoestrogen genistein is reversed by the GSK3beta inhibitor SB 216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione] through mitochondrial ATP-dependent potassium channel opening. J Pharmacol Exp Ther. 2009 Jun;329(3):1134-41. doi: 10.1124/jpet.109.152587. Epub 2009 Mar 24. PubMed PMID: 19318592.
5: Gross ER, Hsu AK, Gross GJ. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1497-500. doi: 10.1152/ajpheart.01381.2007. Epub 2008 Jan 25. PubMed PMID: 18223186.
